Gubra Announces Positive GUBamy Phase 1 Interim MAD Results

April 1, 2025 3:00 AM

Gubra (CPH:GUBRA)GUBamy was well tolerated with adverse events being predominantly GI related, mild and consistent with data from the SAD study.Doses of 1 mg and 2 mg GUBamy administered once-weekly for six weeks led to a dose dependent mean weight loss. LS Mean weight loss in the 2 mg cohort was -7.77% on day 43. In the placebo group there was an LS Mean weight gain of +1.99% on day 43.The body weight loss was sustained in a manner consistent...

Read more

IRLAB to Present Clinical and Preclinical Data at the AD/PD(TM) 2025: 19th International Conference on Alzheimer’s & Parkinson’s Diseases

April 1, 2025 1:20 AM

IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) - Gothenburg, Sweden, April 1, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announced that it will showcase three abstracts at the AD/PD™ 2025: 19th International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, taking place in Vienna, Austria, April 1-5, 2025.Abstract...

Read more

1933 Industries Reports Second Quarter 2025 Financial Results

March 31, 2025 4:40 PM

1933 Industries Inc. (the "Company" or "1933 Industries") (CSE:TGIF(OTC PINK:TGIFF), a Nevada-focused cannabis cultivator and producer, is pleased to announce its second quarter financial results ("Q2 2025") for the three and six months ended January 31, 2025 and 2024 ("Fiscal 2025"). All amounts expressed are in Canadian dollars.The Company owns 91% of Alternative Medicine Association (AMA), the Company's cultivation and production subsidiary...

Read more

Verisante Technology, Inc. Announces Termination of Proposed RTO with SunRegen Healthcare AG

March 31, 2025 4:30 PM

Verisante Technology, Inc. (TSXV:VER.H) ("Verisante") announces that on March 28, 2025, it mutually agreed with SunRegen Healthcare AG ("SunRegen") to terminate the Letter of Intent ("LOI") dated August 12, 2024, to acquire SunRegen Healthcare AG ("SunRegen"), by way of a Reverse Takeover ("RTO").Verisante's common shares were previously halted from trading in connection with a proposed RTO with SunRegen Healthcare AG. Trading of the shares on...

Read more

UNOS Adds Two Members to its Board of Directors

March 31, 2025 2:30 PM

Today, the United Network for Organ Sharing (UNOS) announced that its Board of Directors has unanimously approved two new board members, bringing the board complement to nine.Melina Davis and Mark Johnson will begin their terms on April 1, 2025, serving until September 30, 2028. They were approved by a full board vote on March 24."I'm pleased to welcome Melina and Mark to the UNOS Board of Directors," said Sue Dunn, chair of the UNOS board of...

Read more

Glidewell Partners With Digital Arches to Streamline All-on-X Workflows

March 31, 2025 12:00 PM

Glidewell, industry-leading dental lab and comprehensive provider of surgical and restorative implant solutions, has partnered with Digital Arches to become an official provider of OPTISPLINT®, a high-precision means of enabling digital workflows for All-on-X implant restorations, as well as ARCHTRACER™ fiducial markers. The partnership was established to expand Glidewell's options for capturing and submitting digital impressions for the...

Read more

The Subscription Price for Warrants Series TO 1 in Ascelia Pharma has been Determined to SEK 2.15 and the Exercise Period is Initiated on 1 April 2025

March 31, 2025 12:00 PM

Ascelia Pharma (STO:ACE) - Ascelia Pharma AB ("Ascelia Pharma" or the "Company") (Nasdaq Stockholm: ACE), completed a rights issue of units in September 2024. In connection with the rights issue, Ascelia Pharma issued a total of 20,773,992 warrants series TO 1. One (1) warrant series TO 1 entitles the holder to subscribe for one (1) new ordinary share in the Company. The exercise price for the warrants series TO 1 amounts to seventy (70) percent...

Read more

A Milestone Year - MilliporeSigma Employees Volunteer Over 29,900 Hours in 2024

March 31, 2025 11:00 AM

Giving back to society is more than just a commitment at MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany-it's a core part of the company's culture. In 2024, MilliporeSigma's employee volunteer program, SPARK™, empowered employees to make a meaningful impact in communities worldwide. Through both skills-based and general volunteer efforts, more than 4,100 employees across 29 countries dedicated over...

Read more

VIVA Pediatric Healthcare Expands With Acquisition of Two PPECCs in Longview and Lubbock, Texas

March 31, 2025 10:00 AM

VIVA Pediatric Healthcare proudly announces the expansion of its pediatric care services with the acquisition of two Prescribed Pediatric Extended Care Centers (PPECCs) in Longview and Lubbock, Texas. Lauve's Pediatric Longview and Lauve's Pediatric Lubbock are now officially part of the VIVA Pediatrics family, continuing their commitment to exceptional pediatric care with the same trusted clinical teams and operating hours.This acquisition...

Read more

NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement

March 31, 2025 9:10 AM

NLS Pharmaceutics Ltd.(NASDAQ:NLSP) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders, today announced the closing of a $2 million equity financing of preferred shares at a stated value of $1.65 per share, with a potential second closing of up to an additional $1 million of preferred shares at a purchase price of $1.65 per share. The...

Read more

ZetrOZ Systems to Showcase sam(R) Wearable Ultrasound Unit for Pro Football Trainers

March 31, 2025 9:00 AM

Athletic trainers from all 32 National Football League teams will have the opportunity to learn about the sam® wearable ultrasound unit from ZetrOZ Systems at the upcoming 2025 Professional Football Athletic Trainers Society (PFATS) Meetings.PFATS and the 2025 PFATS Foundation Vendor Show are part of the National Football League (NFL) Medical Summit, running from March 30 to April 5 at the Hilton Orlando Buena Vista Palace in Orlando, Florida....

Read more

Rancho BioSciences Appoints Marc Ginsky as Chief Executive Officer

March 31, 2025 9:00 AM

Rancho BioSciences ("Rancho"), a leader in technology-enabled data science services, today announced that Marc Ginsky has joined as the company's Chief Executive Officer. The company also announced that it has received a majority investment from Arsenal Capital Partners ("Arsenal"), a leading private equity firm specializing in building market-leading, technology-rich healthcare and industrial growth companies.Mr. Ginsky brings decades of...

Read more

Advocacy Organization, Governor Healey, Lawmakers and Medical Experts Recognize Prostate Cancer as a Public Health Priority and Leading Healthcare Disparity

March 31, 2025 8:15 AM

On Thursday March 27th, the AdMeTech Foundation in cooperation with the Prostate Cancer Action Council, Governor Healey, and legislative leaders, teamed up with medical experts, advocates, and prostate cancer survivors and their families, to hold the 16th Annual Prostate Cancer Awareness Day, with the mission to expand a Massachusetts model of national leadership in education and research.Prostate cancer is the most common major malignancy in...

Read more

CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results

March 31, 2025 8:15 AM

CASI Pharmaceuticals, Inc. (NASDAQ:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported business and financial results for the fourth quarter ended December 31, 2024, and provided an update on key highlights for 2024.Wei-Wu He, Ph.D., CASI's Chairman and Chief Executive Officer, commented, "2024 was a...

Read more

Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

March 31, 2025 8:00 AM

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that it has entered into definitive agreements, providing the Company with an aggregate gross proceeds of approximately $1.1 million, for the issuance and sale of an aggregate of 315,188 of its shares of...

Read more

Jaguar Health Reports 2024 Financials: 2024 Net Revenue Up Approximately 20% Over 2023

March 31, 2025 8:00 AM

Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported consolidated financial results for the year ended December 31, 2024.The total net revenue for the Company's prescription products (Mytesi®, Gelclair®, and Canalevia®-CA1), non-prescription products, and license revenue was approximately $11.7 million in the year 2024, representing an increase of approximately 20% versus the total net revenue in the year 2023, which...

Read more

Simulab Corporation Announces Promotion of Woody Salmonsen to Director of Sales, North America

March 31, 2025 8:00 AM

Simulab Corporation, a leader in soft-tissue healthcare simulation training, is pleased to announce the promotion of Woody Salmonsen to Director of Sales, North America.Salmonsen has been with Simulab for seven years and in that time has built strong relationships within the healthcare simulation community as Account Manager for the Northeast and Canada regions. Based in Boston, he's earned the respect of colleagues and educators through his...

Read more

Interactive Strength Inc. (Nasdaq: TRNR) Reports Fourth Quarter & Year-End 2024 Results

March 31, 2025 7:00 AM

Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or the "Company"), maker of innovative specialty fitness equipment under the CLMBR and FORME brands, today announced its financial results for the fourth quarter and full-year of 2024.The Company delivered on its projected quarterly revenue guidance of $2.4 Million - $5.4 million for the full-year - incurring a net quarterly loss of $5.8 million, or $7.26 per diluted share, compared to a loss of...

Read more

Tonix’s Experimental Non-Opioid Analgesic Treatment for Fibromyalgia Could Start Bringing Relief Later This Year

March 31, 2025 7:00 AM

This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work to ensure that any and all information contained within is true and accurate as of the date hereof to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice. Pain...

Read more

Moderna Receives Australian Therapeutic Goods Administration Approval for RSV Vaccine for Older Adults

March 31, 2025 7:00 AM

Moderna, Inc. (NASDAQ:MRNA) today announced that the Australian Therapeutic Goods Administration (TGA) has granted approval for mRESVIA® (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to prevent lower respiratory tract disease caused by RSV infection in adults aged 60 years and older.1 mRESVIA's approval marks a significant milestone as it is the first mRNA vaccine in Australia approved for use against a disease beyond...

Read more